

# CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.

Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440

Email ID: [complianceofficer@concordbiotech.com](mailto:complianceofficer@concordbiotech.com)

May 30, 2026

To The Manager, Listing Department <b>National Stock Exchange of India Limited</b> Plot No. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai -400 051 Symbol: CONCORDBIO	To General Manager, Listing Department <b>BSE Limited</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 543960
--	--

Dear Sir/Ma'am,

**Sub.: Investor's Presentation on audited Standalone and Consolidated Financial Results for the Quarter and financial year ended on March 31, 2026**

Pursuant to Regulation 30 and Schedule III Part A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, "INVESTOR'S PRESENTATION" on audited Standalone and Consolidated Financial Results for the Quarter and financial year ended on March 31, 2026 is enclosed.

Kindly take the above on records.

Thanking you,

**For Concord Biotech Limited**

Paritosh Trivedi

Digitally signed by Paritosh  
Trivedi  
Date: 2026.05.30 12:46:43  
+05'30'

**Paritosh Trivedi**

**Company Secretary and Compliance Officer**

**ACS 63623**

Encl: As above

**CONCORD BIOTECH**



**Concord Biotech Limited**

Investor Presentation – May 2026

# Safe Harbor

This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Concord Biotech Limited** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.

All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness



## **Q4 & FY26 Key Financial Highlights**

# FY26 Key Highlights – Building the Next Phase of Growth

1



## Regulatory Strengthening

- Successfully completed **USFDA, EU GMP, Russian GMP, NAFDAC & WHO-GMP** inspections across multiple facilities
- Reinforces global compliance standards and supports uninterrupted international supplies
- Enhances **trust with global customers** and regulators

2



## Injectables Facility Scaling Up

- Commercialization of our new injectable facility
- Improved revenue visibility with steady traction in injectables business
- **WHO-GMP certification** enables entry into domestic own-brand and contract opportunities
- Strengthens our position in the high-growth injectable market

3



## CDMO & Second Source Opportunities

- Commencement of supplies of Concord APIs to **Two innovator companies**.
- Steady progress in customer acquisitions **for Nystatin** which was launched last year
- Commercialized **Fusidic acid** this year having limited competition mainly from European manufacturers
- **Increasing second-source** opportunities across products
- Active discussions with innovators for generic API supplies & **CDMO projects** which are in advance stages

4



## Building Global Commercial Footprint

- Stellon Biotech obtained all **requisite licenses** with sales expected to commence during the first half of the year.
- **Enables direct marketing, distribution & commercialization** of Concord Biotech's products in the US
- **Strengthens relationships** and accelerates long-term growth in a key regulated market

5



## Investing for Future Growth Platforms

- Entry into **Cell & Gene Therapy** through investment in Cellimune Biotech
- **Incorporated Concord Lifegen** to strengthen domestic formulations strategy
- Company also commenced commercialisation of its **soft gel facility**, creating additional avenues for revenue generation

## FY26 Outcomes



Multiple Global  
**Regulatory  
Clearances**



**Injectable  
Commercialization  
Initiated**



**US Commercial  
Presence Established**



**New Growth Platforms  
Added for the Future**

# Challenges encountered during FY26

## Delay in supply to EU on account of delay in Written Confirmation from CDSCO

Delay in receipt of Written Confirmation from CDSCO for supply in European Union for approx. 3 months



## US Procurement Pattern Shift

Customers adopted staggered quarter-on-quarter procurement instead of bulk, impacting sales volumes with spill over to subsequent year



## Global Tariff & Trade Uncertainty

Uncertainty on tariff situations and global trade war slowed procurement in H1; demand gradually recovered in H2



## Middle East Headwinds On account of geopolitical tensions

Adverse impact due to US-Iran conflict for tender based & routine supplies for middle east territory



## US Veterans Affairs Tender Delay

Related tender not finalised during the year, resulting in lower sales for the current financial year



## Key Focus



Strengthening customer engagement & supply chain agility



Focused on order flow conversion & pipeline visibility



Monitoring global policy changes & mitigation planning




Optimistic on recovery and resumption of supplies


**Challenges were largely timing and transition-led, not structural. We remain confident of improving trend in FY 2026-27.**

# Q4 & FY26 Consolidated Financial Highlights


Revenue (Rs. in Crs)




EBITDA (Rs. in Crs)




PAT (Rs. in Crs)




Gross Profit Margin (%)



EBIDTA Margin (%)




PAT Margin (%)




**EBIDTA margins** (excluding impact of Formulation Facility & Expenses related to newly incorporated subsidiary Stellon Biotech) stood at **40.4%** for Q4FY26 and **38.8%** for FY26

# Q4 & FY26 Segment wise Revenue Split


API Revenue (Rs. in Crs)





Formulation Revenue (Rs. in Crs)





Total Revenue (Rs. in Crs)



API : Formulation




API : Formulation




# Q4 & FY26 Geography wise Revenue Split


### Domestic Revenue (Rs. in Crs)





### Exports Revenue (Rs. in Crs)





### Total Revenue (Rs. in Crs)



### Domestic : Export



### Domestic : Export



# Management Commentary



**Ankur Vaid**

Joint Managing Director &  
Chief Executive Officer

Commenting on the Q4 & FY26 performance of the company Mr. Ankur Vaid, Joint Managing Director & Chief Executive Officer for Concord Biotech Limited said,

*“FY26 was a challenging year for the Company, with revenue impacted by delays in customer procurement decisions, uncertainty related to US tariff measures, and geopolitical disruptions across key markets. In addition, customers shifted from bulk purchasing to a staggered procurement approach amid the prevailing uncertainty, which adversely affected our sales and profitability during the financial year.*

*In response, we have been consistently focusing on product expansion and customer diversification over the past 12–18 months, initiatives that we expect will deliver positive results in the near future. Based on the current order enquiries and a strong customer acquisition pipeline, **we remain highly optimistic about delivering strong outperformance in FY27.***

*During the year, we continued to strengthen our strategic and operational capabilities. We successfully **completed multiple global regulatory inspections** including USFDA, EU-GMP, Russian GMP, NAFDAC and WHO-GMP across facilities, reinforcing our global compliance standards and supporting uninterrupted international supplies.*

*We also progressed commercialization of **our injectable and soft gel facilities, launched Fusidic Acid and commenced supplies to innovator companies.** We also witnessed encouraging **traction in CDMO engagements and second-source opportunities,** supported by evolving global supply chain diversification trends.*

*Further, we strengthened our global commercial footprint through the establishment of Stellon Biotech Inc. in the US and invested in future growth platforms including Cell & Gene Therapy through Cellimmune Biotech, while Concord Lifegen was incorporated to strengthen our domestic formulations strategy.*

*We remain confident of delivering sustainable long-term growth supported by our strong compliance track record, differentiated product portfolio and expanding customer relationships.”*

# Q4 & FY26 Consolidated Profit & Loss Account

Profit and Loss (Rs. in Crs)	Q4FY26	Q4FY25	YoY / Bps	FY26	FY25	YoY / Bps
<b>Revenue from Operations</b>	<b>326.1</b>	<b>429.9</b>	<b>-24%</b>	<b>1,054.9</b>	<b>1,200.1</b>	<b>-12%</b>
Cost of Goods Sold	85.8	128.5		245.7	305.5	
<b>Gross Profit</b>	<b>240.3</b>	<b>301.4</b>	<b>-20%</b>	<b>809.2</b>	<b>894.6</b>	<b>-10%</b>
<b>Gross Profit Margin</b>	<b>73.7%</b>	<b>70.1%</b>	358 bps	<b>76.7%</b>	<b>74.5%</b>	217 bps
Employee Cost	47.8	39.0		176.9	138.9	
Other Expenses	74.0	72.0		264.9	249.3	
<b>EBITDA</b>	<b>118.5</b>	<b>190.4</b>	<b>-38%</b>	<b>367.4</b>	<b>506.3</b>	<b>-27%</b>
<b>EBITDA Margin</b>	<b>36.4%</b>	<b>44.3%</b>	-794 bps	<b>34.8%</b>	<b>42.2%</b>	-736 bps
Depreciation	19.5	14.6		74.5	54.4	
Other Income	15.4	9.4		52.4	44.5	
<b>EBIT</b>	<b>114.4</b>	<b>185.2</b>		<b>345.3</b>	<b>496.4</b>	
Finance Cost	0	0.1		0.3	0.5	
Share in Profit/(loss) in JV and Associates	0	-1.6		2.9	-1.3	
<b>Profit before Tax Exceptional Item</b>	<b>114.1</b>	<b>183.5</b>	<b>-38%</b>	<b>347.9</b>	<b>494.6</b>	<b>-30%</b>
Exceptional Item - Impact on account of Labour Code	0	0		-3.3	0	
<b>Profit before Tax</b>	<b>114.1</b>	<b>183.5</b>		<b>344.6</b>	<b>494.6</b>	
Tax	25.6	43.2		85.4	122.9	
<b>PAT</b>	<b>88.5</b>	<b>140.4</b>	<b>-37%</b>	<b>259.2</b>	<b>371.6</b>	<b>-30%</b>
<b>PAT Margin %</b>	<b>27.1%</b>	<b>32.7%</b>	-552 bps	<b>24.6%</b>	<b>31.0%</b>	-639 bps

# Consolidated Balance Sheet

Assets (in Rs. Crs)	Mar-26	Mar-25
<b>Non - Current Assets</b>	<b>984.6</b>	<b>899.0</b>
Property Plant & Equipment's	785.7	791.8
CWIP	78.2	50.1
Intangible assets	0.3	0.6
Intangible assets under development	1.2	0.5
Goodwill	0.4	-
Right of use asset	2.2	2.3
Investment accounted for using equity method	3.7	0.7
<b>Financial Assets</b>		
Investments	84.9	18.0
Other Financial Assets	6.5	20.6
Other Non-Current Assets	15.9	12.6
Income Tax Assets (Net)	5.8	1.8
<b>Current Assets</b>	<b>1,250.1</b>	<b>1,135.2</b>
Inventories	326.4	239.7
<b>Financial Assets</b>		
(i)Investments	402.1	316.5
(ii)Trade receivables	460.2	521.7
(iii)Cash & cash equivalents and Other Bank Balance	13.6	1.2
Other Financial Assets	25.2	40.8
Other Current Assets	22.7	15.4
<b>Total Assets</b>	<b>2,234.7</b>	<b>2,034.2</b>

Equity & Liabilities (in Rs. Crs)	Mar-26	Mar-25
<b>Total Equity</b>	<b>2,015.1</b>	<b>1,812.7</b>
Share Capital	10.5	10.5
Other Equity	2,006.6	1,802.3
Non Controlling Interest	-1.9	-
<b>Non-Current Liabilities</b>	<b>50.5</b>	<b>37.5</b>
Financial Liabilities		
(i) Lease Liabilities	1.4	0.6
Provisions	3.7	2.8
Deferred Tax Liabilities (Net)	45.4	34.0
<b>Current Liabilities</b>	<b>169.1</b>	<b>184.1</b>
Financial Liabilities		
(i) Borrowings	-	0.4
(ii) Trade Payables	101.9	113.0
(iii) Lease	0.9	2.0
(iv) Other Financial Liabilities	42.7	41.7
Other Current Liabilities	12.3	11.3
Current tax liabilities (Net)	0.0	10.1
Provisions	11.2	5.5
<b>Total Equity &amp; Liabilities</b>	<b>2,234.7</b>	<b>2,034.2</b>

# Abridged Cashflow Statement

Particulars (in Rs. Crs)	FY26	FY25
<b>Net Profit Before Tax</b>	<b>344.6</b>	<b>494.6</b>
Adjustments for: Non -Cash Items / Other Investment or Financial Items	36.5	30.1
<b>Operating profit before working capital changes</b>	<b>381.2</b>	<b>524.7</b>
Changes in working capital	-13.9	-170.8
<b>Cash generated from Operations</b>	<b>367.3</b>	<b>353.9</b>
Direct taxes paid (net of refund)	-100.4	-109.4
<b>Net Cash from Operating Activities</b>	<b>266.9</b>	<b>244.5</b>
<b>Net Cash from Investing Activities</b>	<b>-142.7</b>	<b>-160.0</b>
<b>Net Cash from Financing Activities</b>	<b>-112.9</b>	<b>-98.8</b>
<b>Net Decrease in Cash and Cash equivalents</b>	<b>11.3</b>	<b>-14.2</b>
Add: Cash & Cash equivalents at the beginning of the period	0.9	15.1
<b>Cash &amp; Cash equivalents at the end of the period</b>	<b>12.2</b>	<b>0.9</b>



**Formulation Facility**  
Valthera, Ahmedabad, India



**API Facility**  
Dholka, Ahmedabad, India



**API Facility**  
Limbasi, Ahmedabad, India

# Company Overview

# Concord Biotech at a Glance

Concord Biotech Limited is a R&D driven biopharma Company that manufactures **Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations.**

## Key Highlights

Portfoliospanning  
**30+**  
FermentationAPIs

**150+**  
DrugMasterFiles  
(DMFs) filedglobally

**100+**  
Approved  
formulationproducts  
acrossmarkets

Fermentation  
capacityof  
**1,250m<sup>3</sup>**

**5**  
ANDAs approved for products  
from our facilities

Overall formulation  
manufacturingcapacity of  
**802Mn Units**



**Expertise in Fermentation Technology**

- ✓ **Expertise in fermentation**-based API manufacturing with high entry barriers
- ✓ One of the few global players **delivering consistently** in this specialized segment
- ✓ Built one of the **largest fermentation capacities globally**



**Continuous Investment in R&D Driven Innovation**

- ✓ **Strong focus on R&D** & State-of-the-art R&D facilities.
- ✓ Dedicated **team of scientists**.
- ✓ **Commitment to innovation** enables us to stay ahead of market trends.
- ✓ **Robust pipeline** for addition of **new products** to meet evolving market demands



**Upholding the Highest Standards of Quality and Compliance**

- ✓ **World-class infrastructure** adhering to global quality benchmark
- ✓ Facilities inspected by **USFDA, EU GMP, WHO, and PMDA, Japan**
- ✓ Presence in **over 70 countries**, including regulated markets



**Driven by Expertise and Consistent Performance**

- ✓ **Visionary leadership** driving consistent growth and global expansion
- ✓ Evolved from single-product to **multi-product company**
- ✓ Focus on fermentation, research, manufacturing, and compliance
- ✓ Positioned for **sustained leadership through innovation**

# Driving Innovation Through Our Expertise

## Mission Focus


Dedicated to deliver high-quality product that enhance human health, driven by innovation and customer centricity, fostering partnerships that make a meaningful impact

## Visionary Leadership

Led by industry veterans. Our strategic decisions help us navigate challenges and drive sustained growth. This positions us as a trusted industry leader, committed to shaping a healthier tomorrow

## Regulatory Compliance

Rigorous adherence to regulatory standards is integral to our operations, ensuring product integrity and customer trust, bolstering our reputation as a reliable partner in healthcare



## Fermentation Expertise

Through our strong fermentation capabilities, we produce high-quality APIs, setting us apart in biotechnology and ensuring superior efficacy in medicines

## Diversified Portfolio

We offer full baskets of immunosuppressants in addition to our products in oncology and anti infectives making total count of 30+ fermentation-based API's. This helps in ensuring resilience against market fluctuations and meeting diverse pharmaceutical needs effectively

## Commitment to Innovation

Our heavy investment in R&D drives continuous process optimization, new product development, and industry leadership, fueling breakthroughs that shape the future of healthcare

# API Business Overview

## API Overview

One of the **leading global** developers and manufacturers of **Fermentation-based APIs**

Focus on **Niche Fermentation API's** with **backward integration** to Key Starting Material

Diversified Product Portfolio of API's including **Immuno-suppressant, Oncology, Anti-Infectives & Anti-Fungal**

## Key Products

### Immunosuppressant

- ✦ Tacrolimus
- ✦ Mycophenolate Mofetil
- ✦ Mycophenolate Sodium
- ✦ Cyclosporine
- ✦ Sirolimus
- ✦ Pimecrolimus
- ✦ Everolimus Premix 2%
- ✦ Voclosporin

### Oncology

- ✦ Temsirolimus
- ✦ Everolimus
- ✦ Romidepsin
- ✦ Mitomycin
- ✦ Dactinomycin
- ✦ Staurosporin
- ✦ Midostaurne
- ✦ Everolimus Premix 9.09%

### Antibacterial

- ✦ Mupirocin
- ✦ Mupirocin Calcium
- ✦ Polymyxin B Sulfate
- ✦ Teicoplanin
- ✦ Vancomycin Hydrochloride
- ✦ Fidaxomicin

### Antifungal

- ✦ Anidulafungin
- ✦ Caspofungin Acetate
- ✦ Micafungin Sodium
- ✦ Amphotericin B
- ✦ Nystatin

### Others

- ✦ Lovastatin
- ✦ Pravastatin Sodium
- ✦ Enzymes

FY26 – **Rs~ 829** Crores Revenue

FY26 – **79%** Revenue Split

**30+** Fermentation APIs

# Formulation Business Overview

## Formulation Overview

Commercialization of Formulations business in 2016 to capitalize on the **benefits of backward integration**

Operate through **B2B model** across regulated and emerging markets  
For India Market, operate via **B2B & B2C model**

**Oral Solid Dosages** (tablets, capsules and oral suspension)  
**Injectables** (Liquid Vials, Dry Powder Filling, Sterile Lyophilized APL)

## Key Products

### Antifungal

- CRITICAL CARE**
- ★ Amfoterol™
  - ★ Anicord™
  - ★ Caspocon™
  - ★ Micacord™
  - ★ Vorixia™
  - ★ Picocord GR™
- ★ Isacrest™

### Antibiotics

- CRITICAL CARE**
- ★ Dapute™
  - ★ Fosutrac™
  - ★ Pobix™
  - ★ Teicocord™
  - ★ Vanogard™
  - ★ Cricolist™
  - ★ Avycord™
- ★ Mepecon™
  - ★ Mepecon
  - ★ Minocrit™
  - ★ Tigicon™
  - ★ Primataz™
  - ★ Muprevent™
  - ★ Clarinazest™
  - ★ NextMatch™

### Plasma Products

- CRITICAL CARE**
- ★ Gamacon™
  - ★ Obulin™
- RHEUMATOLOGY**
- ★ Conimab
  - ★ Gammacord

### Transplant & Immuno

- NEPHROLOGY**
- ★ Tacrocord
  - ★ Mofecon
  - ★ Evercon
  - ★ Conimune ME
  - ★ Cyclograf
  - ★ Valocon
  - ★ Conimab

### Chronic Kidney Disease

- NEPHROLOGY**
- ★ Darbecon
  - ★ Epocord
  - ★ Sevecord
  - ★ Coniron
  - ★ Cinacet
  - ★ Valolog
  - ★ Injecarb
- ★ Upshield
  - ★ Milipro
  - ★ Nabosis
  - ★ Kalcord
  - ★ Picatol
  - ★ Kanilev
  - ★ Lavits

### Immunology

- RHEUMATOLOGY**
- ★ Adacord
  - ★ Arthimide 1
  - ★ Arthimide 2
  - ★ Conimab 1
  - ★ Conimab 2
  - ★ Conimmune 25
  - ★ Mabdeno
- ★ Cyclograp
  - ★ Mofecon 250
  - ★ Tacrocord 0.25
  - ★ Tofajoint ER
  - ★ Tofajoint
  - ★ Unuric 40
  - ★ Pricroda

FY26 – **Rs ~ 226** Crores Revenue

FY26 – **21%** Revenue Split

**100+** Approved Products

# Trusted CDMO partner for Fermentation & Semi-Synthetic API's

## CDMO Overview

Provide **contract research and manufacturing services** for developing APIs and formulations.

Prioritizes innovation, **backed by a DSIR-certified R&D facility** with a team of 180+ people

**Expertise in fermentation technology** and **strong R&D infrastructure** enable us to undertake complex projects and deliver **high-quality outcomes**

## Key Strengths & Opportunities

- **Advanced fermentation capabilities**, expertise in strain isolation and enhancement, and scalable processes
- Facilitates **smooth transitions from lab research to full-scale production**
- **Specializes in Contract Research & Manufacturing**, with a focus on fermentation and semi-synthesis
- **Ample capacities** with necessary regulatory approvals **to ensure smooth & consistent supply**



## Services Include

- ❖ **Strain Improvement**
- ❖ **Media Optimization**
- ❖ **Process Development**
- ❖ **Downstream Processing**

# Pushing Boundaries through Manufacturing Capabilities

## Unit I (API) – Dholka, Gujarat



**FY2000** Operations commenced

**1,12,302 sq.m.** Spread across

**450 m<sup>3</sup>** Installed capacity

## Unit III (API) – Limbasi, Gujarat



**FY2021** Operations commenced

**5,96,309 sq.m.** Spread across

**800 m<sup>3</sup>** Installed capacity

## Unit II (Formulations) – Valthera, Gujarat



**FY2016** Operations commenced

**94,826 sq.m.** Spread across

**802Mn Units** Installed capacity

## Unit IV (Injectables) – Valthera, Gujarat



**FY2025** Operations commenced

**36,441 sq.m.** Spread across

Installed capacity of **13Mn** Liquid Vials,  
**12Mn** Dry Power Filling & **2,200** Kgs  
Sterile Lyophilized APL

# Pioneering R&D Capabilities

180

R&D Employee Strength

7/5

Approved ANDA/  
Finished Products

> 150

API DMFs

22+

Non-Infringing Processes

Spends as % of Sales

3.6%

26

2022

3.5%

30

2023

2.2%

23

2024

2.3%

27

2025

2.8%

29

2026

R&D Spends (Rs in. Crs)

Robust pipeline of **more than 10 products** across different therapeutic segments of Oncology, Anti-Infectives & Anti-Fungal

## R&D Initiatives:

Cost Improvement

New Product Development

Process Improvement

Technology Transfer

Scale-Up Initiatives

Enhancement of Backward Integration

## State-of-the-Art Facilities: Where Ideas Materialise

### API R&D Lab

- Specialized capabilities for isolation of strains, mutation, and passive selection of microbial strains, as well as strain improvement processes.
- Our R&D strengths enable us to drive innovation and develop new active pharmaceutical ingredients efficiently
- Equipped with fermenters and a pilot plant facility, allowing us to seamlessly scale up fermentation processes from lab scale to commercial production scale.

Our integrated R&D capabilities across API and formulations development allow us to bring new and innovative pharmaceutical products to the market effectively.

### Formulations R&D Lab

- Focus on formulation development leveraging advanced analytical capabilities.
- R&D team works closely with our API experts to ensure our products meet the highest standards of quality and efficacy while providing optimal drug delivery and patient convenience

# DMF Fillings Across Geographies

Molecules	US	EU	Canada	Japan	China	
Immuno-Suppressants	Tacrolimus	✓	✓	✓	✓	
	Mycophenolate Mofetil	✓	✓	✓	✓	
	Mycophenolate Sodium	✓	✓	✓	✓	
	Cyclosporine	✓	✓	✓	✓	
	Sirolimus	✓	✓	✓	✓	
	Pimecrolimus	✓				
	Voclosporin	✓				
Oncology	Temsirolimus	✓	✓			
	Everolimus	✓	✓	✓	✓	
	Romidepsin	✓				✓
	Mitomycin	✓	✓	✓		
	Dactinomycin	✓				
	Midostaurin	✓				
	Mupirocin	✓	✓	✓		✓
Anti-Bacterial	Nystatin	✓	✓			
	Mupirocin Calcium	✓	✓	✓		
	Vancomycin Hydrochloride	✓	✓			
	Others	Lovastatin	✓	✓		
Pravastatin Sodium		✓	✓			

# Wide Range of Formulation Product Portfolio for Overseas Markets

## Regulated Markets

Product Name	ANDA Approval
Mycophenolate Mofetil Capsules	✓
Mycophenolic Acid DR Tablets USP	✓
Mycophenolate Mofetil Tablets	✓
Tacrolimus Capsules USP	✓
Teriflunomide Tablets	✓

## Emerging Markets

Product Name
Mycophenolate Mofetil Capsules
Mycophenolate Mofetil Tablets
Mycophenolate Mofetil Suspension
Mycophenolate Sodium 180mg Tablets
Mycophenolate Sodium 360mg Tablets
Tacrolimus 0.5mg Capsules
Tacrolimus 1mg Capsules
Tacrolimus 5mg Capsules

# Diversified Customer Base



**Worldwide Presence**

**Tailored Distribution Models**

**Collaborative Partnerships**




**70+  
Countries**



**250+  
Customers**

Reducing Customer Concentration % Contribution from Top 10 Customers



# Paving the Way for Sustainability

## Our Vision for Sustainability

Sustainable Manufacturing

Global Green Leadership

Environmental Conservation

## The Path of Sustainability

Research & Development

Efficient Resource Management

Constant Improvement & Adaptation



## Awarded Bronze Medal by EcoVadis



## Our Initiatives on Sustainability

- ✓ Corporate Social Responsibility
- ✓ Driving towards sustainable future
- ✓ Reduced ecological harm
- ✓ Improved water quality



**Received**  
**ISO-14001:2015 & ISO-45001:2018**  
**Certifications**




**Key Business Differentiators**

# End-to-End Expertise in Complex Fermentation Value Chain



## Leadership Position

Leadership position for select molecules in global markets




1,250 M<sup>3</sup>

Fermentation Capacity across two API facilities



## Over 2 Decades

Experience in the industry with a demonstrated track record of developing niche and complex molecules



## 30+ Fermented based APIs

One of leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants oncology and Anti-infectives in terms of market share

## Overview of Integrated Platform



R&D



Patents



Key Starting Material



API Manufacturing



Formulations




Marketing & Distribution



# Constructing Formidable Barriers to Entry



**Complex technical capabilities**, difficulties in scaling up operations and substantial capital investment required have resulted in **significant barriers to entry** in the fermentation-based API space



# Key Growth Drivers



**For further Information, please contact**

**Company:**

**CONCORD BIOTECH**

**Concord Biotech Limited**

CIN: L24230GJ1984PLC007440

Mr. Raviraj Karia – Chief Financial Officer

[ravirajkaria@concordbiotech.com](mailto:ravirajkaria@concordbiotech.com)

[www.concordbiotech.com](http://www.concordbiotech.com)

**Investor Relations Advisor:**

**SGA** Strategic Growth Advisors

**Strategic Growth Advisors Pvt. Ltd.**

CIN - U74140MH2010PTC204285

**Mr. Sagar Shroff / Mr. Vatsal Shah**

[sagar.shroff@sgapl.net](mailto:sagar.shroff@sgapl.net) / [vatsal.shah@sgapl.net](mailto:vatsal.shah@sgapl.net)

+91 98205 19303 / +91 88796 59884

[www.sgapl.net](http://www.sgapl.net)